Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback